The National Institute on Drug Abuse is funding research on ibogaine for the potential treatment of opioid use disorder in adults.

Overview Debates Related claims Topics Sources

Calley Means and his statement on October 22, 2026 highlighted Make America Healthy Again policy achievements, including expanding access to psychedelics, overhauling dietary guidelines, and limiting SNAP benefits for sugary drinks

The proposed FY26 budget restructuring includes a $1 billion funding reduction affecting community mental health centers, suicide prevention, and substance use treatment programs.

The President's FY26 budget proposed dissolving the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration to consolidate them into a new Administration for a Healthy America.

The Substance Abuse and Mental Health Services Administration reinstated $2 billion in mental health and substance use grants on January 14, 2026, following bipartisan pushback.

On January 13, 2026, the Substance Abuse and Mental Health Services Administration terminated hundreds of grants totaling approximately $2 billion for mental health and substance use disorder services.

Heavy alcohol use, drug use, and smoking were associated with looking biologically older in FAHR-FaceAge facial photograph analyses, with current smokers appearing older than former smokers.

A study in BMJ Open associated childhood adversity with 60% of drug use in Wales, 57% in England, 49% of violence in Wales, and 46% in England.

Ultra-processed food and addiction researcher Ashley Gearhardt noted that binge eating emerged as a recognized clinical problem alongside the growing dominance of highly processed foods in the food supply.

Former NIMH Director Steven Hyman warned at the STAT Summit that psychiatry lacks objective biomarkers to determine which patients will benefit from psychedelic treatments.

Compass Pathways expects COMP360 to be subject to an FDA risk evaluation and mitigation strategy (REMS) upon approval and is investing in provider training for drug administration.

Compass Pathways CEO Kabir Nath stated at the STAT Summit that the company will go slow before it goes fast ahead of the COMP360 FDA submission to avoid early negative patient or provider experiences.

In Compass Pathways Phase 3 trials, roughly 40% of treatment-resistant depression patients experienced a clinically meaningful response after receiving two doses of COMP360 three weeks apart.

Compass Pathways CEO Kabir Nath stated on October 14, 2026, that the company plans to complete its rolling FDA submission for COMP360 synthetic psilocybin treatment in the fourth quarter of 2026.

Former NIMH Director Steven Hyman noted that functional unblinding remains a clinical trial challenge because patients recognize the subjective effects of psychedelic drugs, citing FDA's 2024 rejection of Lykos Therapeutics' MDMA therapy.

Compass Pathways CEO Kabir Nath stated that COMP360 clinical trial session recordings revealed patients spent approximately 80% of session time in silence after the company deliberately separated psychotherapy from trial protocols.

Compass Pathways is engaging commercial insurers and CMS regarding reimbursement mechanisms for clinical monitoring required during COMP360 psilocybin treatment sessions.

COMP360 psilocybin treatment holds Breakthrough Therapy designation from the U.S. FDA and Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression.

Documented marijuana use among young adult stroke patients in the study region increased from under 1% in 1993–1994 to 30.6% in 2020, accounting for most of the overall substance use increase.

Documented substance use among stroke patients aged 20 to 54 increased from 4.6% in 1993–1994 to 40.2% in 2020.

The planned 2027 Pittsburgh GLP-1 trial will evaluate whether the drug helps individuals with addiction while reducing criminal recidivism and improving employment, health, and housing outcomes.